1 hour ago
9
ChronoScale Holdings Corporation (NASDAQ: CHRN) says its total contracted run-rate revenue has reached $1 billion. It got there by extending one deal with an AI infrastructure client and signing a new one.
On October 1, 2026, the Dallas-based company paired that milestone with another move: it announced the sale of its legacy Ekso Bionics exoskeleton business. A company that until recently made wearable robotics now wants to be judged purely as an AI compute shop.
From exoskeletons to GPUs
ChronoScale describes itself as a provider of accelerated compute infrastructure built for AI. It runs high-density AI workloads out of colocation facilities, offering a bundle of compute, networking, storage, cooling and software services.
The new contracts announced on October 1 lifted the company’s total contracted run-rate revenue to $1 billion. Run-rate figures typically annualize the value of signed agreements. That makes them a measure of what is lined up, not cash already collected.
The company has also set a goal of reaching $1 billion in revenue by Q3 2027.
In the fiscal year that ended May 31, 2026, ChronoScale reported revenue of $71.6 million. Most of it came from a single customer, Together AI, under a recurring contract. The same year brought a net loss of approximately $50.3 million.
The Microsoft and Nutanix deals
The biggest name on the client roster is Microsoft. ChronoScale initially signed that agreement on August 6, 2026, and laid out the details on August 27, 2026.
The partnership covers a 50 megawatt (MW) deployment of AI compute capacity in North America. It will run on NVIDIA’s GB300 NVL72 systems, rack-scale machines built for large AI training and inference jobs.
ChronoScale is targeting completion of the Microsoft buildout by Q1 2027.
A few weeks before the Microsoft details came out, ChronoScale announced a strategic partnership with Nutanix on August 18, 2026. That arrangement is aimed at speeding up enterprise adoption of AI infrastructure.
A company built in a hurry
ChronoScale is barely half a year old in its current form. It was created in May 2026 by merging Applied Digital’s cloud business with Ekso Bionics Holdings.
Leadership has been rebuilt on a similarly fast schedule. Cenly Chen was appointed CEO in May 2026. Raj Jegannathan joined as chief technology officer and Lawrence Lam as chief product officer, both in June 2026.
What this means for investors and customers
The clearest story here is concentration risk. Last fiscal year, one customer, Together AI, generated most of the revenue. Adding Microsoft and Nutanix spreads that exposure across more names.
The Microsoft deployment is the milestone to watch. Hitting the Q1 2027 completion target would show the company can deliver large-scale capacity on schedule. The revenue target for Q3 2027 leans heavily on capacity actually coming online.
A net loss of approximately $50.3 million on $71.6 million in revenue shows a business still spending heavily to grow. Building out 50 MW of GB300 capacity is not cheap, and investors will likely watch how ChronoScale funds the expansion.
Shedding Ekso Bionics simplifies the pitch. Investors no longer need to value an exoskeleton maker and an AI cloud operator under one ticker. CHRN now rises or falls on a single question: can it turn signed contracts into running, revenue-generating compute.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.
English (US) ·